Budesonide as first-line therapy for non-cirrhotic autoimmune hepatitis in children: a decision analysis

References

• Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol. 2011;8:320–329.
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31:929–938.
   PubMed Web of Science ®Google Scholar
• Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.
   PubMed Web of Science ®Google Scholar
• Suchy FJ, Sokol RJ, Balistreri WF. Liver disease in children. 3rd ed. Cambridge; New York: Cambridge University Press; 2007.
   Google Scholar
• Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25:541–547.
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319–333.
   PubMed Web of Science ®Google Scholar
• Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr. 2006;43: 629–634.
   PubMed Web of Science ®Google Scholar
• Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53: 191–198.
   PubMed Web of Science ®Google Scholar
• Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann Pharmacother. 2011;45: 1144–1150.
   PubMed Web of Science ®Google Scholar
• Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.
   PubMed Web of Science ®Google Scholar
• Woynarowski M, Nemeth A, Baruch Y, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163:1347–1353.
   PubMed Web of Science ®Google Scholar
• Mieli-Vergani G, Vergani D. Budesonide for juvenile autoimmune hepatitis? Not yet. J Pediatr. 2013;163: 1246–1248.
   PubMed Web of Science ®Google Scholar
• Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196–202.
   PubMed Web of Science ®Google Scholar
• Efe C, Ozaslan E, Kav T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. 2012;11:330–334.
   PubMed Web of Science ®Google Scholar
• Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9:2681–2685.
   PubMed Web of Science ®Google Scholar
• Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339–1341.
   PubMed Web of Science ®Google Scholar
• Canada Drugs. 2013. Available from: https://www.canadadrugs.com/.
   Google Scholar
• Ladapo JA, Neumann PJ, Keren R, et al. Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US. Pharmacoeconomics. 2007;25:817–828.
   PubMed Web of Science ®Google Scholar
• Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115: e600–e614.
   PubMed Web of Science ®Google Scholar
• Mohammad S, Li Z, Englesbe M, et al. Withdrawal of immunosuppression following pediatric liver transplantation. A Markov snalysis. J Pediatr Gastroenterol Nutr. 2014;59:182–189.
   PubMed Web of Science ®Google Scholar
• Feeny D, Furlong W, Saigal S, et al. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons. Soc Sci Med. 2004;58:799–809.
   PubMed Web of Science ®Google Scholar
• Grootendorst P, Feeny D, Furlong W. Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med Care. 2000; 38:290–299.
   PubMed Web of Science ®Google Scholar
• Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom. Med Decis Making. 2005;25:56–70.
   PubMed Web of Science ®Google Scholar
• Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155:21–25. 25 e1-5.
   PubMed Web of Science ®Google Scholar
• Burnand B, Kernan WN, Feinstein AR. Indexes and boundaries for “quantitative significance in statistical decisions.” J Clin Epidemiol. 1990;43:1273–1284.
   PubMed Web of Science ®Google Scholar
• De Tommaso AM, Santos DS, Novaes P, et al. Steroid-induced cataracts in patients with autoimmune hepatitis. Acta Gastroenterol Latinoam. 2003;33:93–97.
   PubMedGoogle Scholar
• Dobbels F, Van Damme-Lombaert R, Vanhaecke J, et al. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005;9:381–390.
   PubMed Web of Science ®Google Scholar
• George M, Freedman TG, Norfleet AL, et al. Qualitative research-enhanced understanding of patients' beliefs: results of focus groups with low-income, urban, African American adults with asthma. J Allergy Clin Immunol. 2003;111:967–973.
   PubMed Web of Science ®Google Scholar
• Vitfell-Pedersen J, Jorgensen MH, Muller KC, et al. Autoimmune hepatitis in children in Eastern Denmark. J Pediatr Gastroenterol Nutr. 2012;55:376–379.
   PubMed Web of Science ®Google Scholar
• Deneau M, Book LS, Guthery SL, et al. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study. J Pediatr. 2014;164:714e2–719e2.
   Web of Science ®Google Scholar
• Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585–590.
   PubMed Web of Science ®Google Scholar
• Bhat M, Ghali P, Wong P, et al. Immunosuppression with budesonide for liver transplant recipients with severe infections. Liver Transpl. 2012;18:262–263.
   PubMed Web of Science ®Google Scholar
• Weber T, Kalbhenn T, Herrmann G, et al. Local immunosuppression with budesonide after liver transplantation in the rat: a preliminary histomorphological analysis. Transplantation. 1997;64:705–708.
   PubMed Web of Science ®Google Scholar
• Gulati R, Radhakrishnan KR, Hupertz V, et al. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr. 2013;57:444–450.
   PubMed Web of Science ®Google Scholar
• Ngu JH, Gearry RB, Frampton CM, et al. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology. 2013;57: 2399–2406.
   PubMed Web of Science ®Google Scholar
• Cicalese MP, Iorio R. Management of autoimmune hepatitis in children: how many steps away from common agreement? J Pediatr Gastroenterol Nutr. 2012;55:364.
   PubMed Web of Science ®Google Scholar
• Tong A, Wong G, McTaggart S, et al. Quality of life of young adults and adolescents with chronic kidney disease. J Pediatr. 2013;163:1179–1185.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Maker D, Grundland B, et al. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs). Med Decis Making. 2003;23:314–322.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–749.
   PubMed Web of Science ®Google Scholar
• Chiou CF, Weaver MR, Bell MA, et al. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care. 2005;17:23–30.
   PubMed Web of Science ®Google Scholar